Features

J&J plans to separate its pharma and medical devices businesses into one company and its consumer health business into another company. What’s behind the new J&J?

CDMOs/CMOs are an integral part of bio/pharmaceutical companies’ manufacturing networks. A roundup of biomanufacturing expansion projects.

Drug-pricing reform in the US is on the table once again as Congress and the Biden Administration seek to move forward with a new plan. What’s in the plan?

Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand.

Novartis is starting a strategic review of Sandoz, its generics and biosimilars business. Is another wave of industry consolidation in the generics industry on tap?

The FDA has approved 42 new molecular entities thus far in 2021. Which products launched or expected to be launched in 2021 have blockbuster potential?

The FDA has issued draft guidance for continuous manufacturing of drug substances and drug products. Industry feedback is due by mid-December. What does the FDA say? 

Manufacturing 4.0 is used to denote “smart factories” with increased levels of digitalization and automation. Where does the bio/pharma industry stand?

The global bio/pharma market is projected to reach $1.6 trillion by 2025. What’s the outlook for the US, Europe, other markets and key product areas?

Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan?